Dynamic changes of inflammation-related indices in venous thromboembolism and the association between these indices and venous thromboembolism

National Medical Journal of China

Volumn 93, Issue 24, 2013, Pages 1860-1863

  Liu, Fang Fang ^a   Zhai, Zhen Guo ^a   Yang, Yuan Hua ^a   Wang, Jun ^c   Wang, Chen ^b  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b BEIJING HOSPITAL   (China)

^c Ministry of Health ^*

Author keywords

Blood sedimentation; C reactive protein; Fibrinogen; Leukocytes; Venous thrombosis

Indexed keywords

C REACTIVE PROTEIN; FIBRINOGEN;

ARTICLE; BODY MASS; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; GENDER; HUMAN; INFLAMMATION; LEUKOCYTE; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL; PROTEIN BLOOD LEVEL; PULMONARY ARTERY; SMOKING; VENOUS THROMBOEMBOLISM;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BLOOD SEDIMENTATION; C-REACTIVE PROTEIN; FEMALE; FIBRINOGEN; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; NEUTROPHILS; RISK FACTORS; VENOUS THROMBOEMBOLISM; YOUNG ADULT;

EID: 84880002591     PISSN: 03762491     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0376-2491.2013.24.002     Document Type: Article

References (17)

1. Kahn S R, Shrier I, Julian J A, et al. Determinants and time course of the post thrombotic syndrome after acute deep venous thrombosis. Ann Intern Med, 2008, 149:698-707.
2. Condliffe R, Kiely D G, Gibbs J S, et al. Prognostic and aetiological factors in chronic thromboembolic pulmonary hypertension. Eur Respir J, 2009, 33:332-338.
3. 2012, 92:1807-1809.
4. Van Aken B E, Den Heijer M, Bos G M, et al. Recurrent venous thrombosis and markers of inflammation. Thromb Haemost, 2000, 83:536-539.
5. Zee R Y, Glynn R J, Cheng S, et al. An evaluation of candidate genes of inflammation and thrombosis in relation to the risk of venous thromboembolism: The Women's Genome Health Study. Circ Cardiovasc Genet, 2009, 2:57-62.
6. Tsai A W, Cushman M, Rosamond W D, et al. Coagulation factors, inflammation markers, and venous thromboembolism: The longitudinal investigation of thromboembolism etiology (LITE). Am J Med, 2002, 113:636-642.
7. 2003:496.
8. Connolly G C, Khorana A A, Kuderer N M, et al. Leukocytosis, thrombosis and early mortality in cancer patients initiating chemotherapy. Thromb Res, 2010, 126:113-118.
9. Reitsma P H, Branger J, Van Den Blink B, et al. Procoagulant protein levels are differentially increased during human endotoxemia. J Thromb Haemost, 2003, 1:1019-1023.
10. Fibrinogen Studies Collaboration, Danesh J, Lewington S, et al. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: An individual participant metaanalysis. JAMA, 2005, 294:1799-1809.
11. Kamphuisen P W, Eikenboom J C, Vos H L, et al. Increased levels of factor VIII and fibrinogen in patients with venous thrombosis are not caused byacute phase reactions. Thromb Haemost, 1999, 81:680-683.
12. Palareti G, Cosmi B. Predicting the risk of recurrence of venous thromboembolism. Curr Opin Hematol, 2004, 11:192-197.
13. Rumley A, Emberson J R, Wannamethee S G, et al. Effects of older age on fibrin D-dimer, C-reactive protein, and other hemostatic and inflammatory variables in men aged 60-79 years. J Thromb Haemost, 2006, 4:982-987.
14. Folsom A R, Lutsey P L, Astor B C, et al. C-reactive protein and venous thromboembolism: A prospective investigation in the ARIC cohort. Thromb Haemost, 2009, 102:615-619.
15. Zacho J, Tybjaerg-Hansen A, Nordestgaard B G. C-reactive protein and risk of venous thromboembolism in the general population. Arterioscler Thromb Vasc Biol, 2010, 30:1672-1678.
16. Chiang C W, Santos R D, Waters D D, et al. Reaching C-reactive protein and low-density lipoprotein cholesterol goals in dyslipidemic patients (from the Lipid Treatment Assessment Project [L-TAP]2). Am J Cardiol, 2011, 107:1639-1643.
17. Fichtlscherer S, Rosenberger G, Walter D H, et al. Elevated C-reactive protein levels and impaired endothelial vasoreactivity in patients with coronary artery disease. Circulation, 2000, 102:1000-1006.